直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 114570
著者
Ohnuma, Hiroyuki Sapporo Medical University
Hayasaka, Naotaka Sapporo Medical University
Matsuno, Teppei Sapporo Medical University
Fujita, Chisa Sapporo Medical University
Sato, Masanori Sapporo Medical University
Osuga, Takahiro Sapporo Medical University
Hirakawa, Masahiro Sapporo Medical University
Miyanishi, Koji Sapporo Medical University
Sagawa, Tamotsu Hokkaido Cancer Center
Fujikawa, Koshi Hokkaido Cancer Center
Ohi, Motoh Sapporo Kyoritsu Gorinbashi Hospital
Okagawa, Yutaka Tonan Hospital
Tsuji, Yasushi Tonan Hospital
Hirayama, Michiaki Tonan Hospital
Ito, Tatsuya Sapporo Medical University
Nobuoka, Takayuki Sapporo Medical University
Takemasa, Ichiro Sapporo Medical University
Kobune, Masayoshi Sapporo Medical University
Kato, Junji Sapporo Medical University
キーワード
docetaxel
esophageal cancer
esophageal squamous cell carcinoma
nedaplatin
neoadjuvant chemotherapy
資料タイプ
学術雑誌論文
抄録
Cisplatin plus 5‐fluorouracil is regarded as standard neoadjuvant chemotherapy for esophageal squamous cell carcinoma (ESCC) in Japan, but the prognosis remains poor. We have previously described how definitive chemoradiotherapy with docetaxel, nedaplatin, and 5‐fluorouracil (DNF) led to a very high response rate and promising survival times. We therefore undertook a phase II trial to evaluate the feasibility and efficacy of neoadjuvant DNF. The study included patients with clinical stage Ib‐III ESCC. Chemotherapy consisted of i.v. docetaxel (30 mg/m2) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infusion of 5‐fluorouracil (400 mg/m2/day) on days 1‐5 and 8‐12, every 3 weeks. After three courses of chemotherapy, esophagectomy was carried out. The primary end‐point was the completion rate of the protocol treatment. Twenty‐eight patients were enrolled (cStage Ib/II/III, 2/3/23) and all received at least two cycles of chemotherapy. Twenty‐five patients underwent surgery, all of whom achieved an R0 resection, leading to a completion rate of 89.3%. The overall response rate was 87.0%. A pathological complete response was confirmed in eight (32.0%) cases. Grade 3/4 adverse events included leukopenia (32.1%), neutropenia (39.3%), febrile neutropenia (10.7%), thrombocytopenia (10.7%), and diarrhea (14.3%), but were manageable. Treatment‐related deaths and major surgical complications did not occur. Estimated 2‐year progression‐free and overall survival rates were 70.4% and 77.2%, respectively. Thus, DNF therapy was well tolerated and deemed feasible, with a strong tumor response in a neoadjuvant setting for ESCC. This trial is registered with the University Hospital Medical Information Network (UMIN ID: 000014305).
掲載誌名
Cancer Science
ISSN
13497006
出版者
Japanese Cancer Association|John Wiley & Sons
109
11
開始ページ
3554
終了ページ
3563
発行日
2018-08-23
権利情報
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系